

FIG. 1
Responders at all three time-points




FIG. 2
Median % change from baseline: migraine days per month
Median ($\pm$ IQR) percentage change from baseline in migraine days
per month: AB6 versus Placebo




FIG. 3
Median % change from baseline: migraine episodes per month
Median ($\pm$ IQR) percentage change from baseline in migraine episodes per month: AB6 versus Placebo




FIG. 4
Median % change from baseline: migraine hours per month
Median ($\pm$ IQR) percentage change from baseline in migraine hours
per month: AB6 versus Placebo




FIG. 5




FIG. 6
Mean Change Baseline HIT-6 score
Mean ($\pm$ SD) absolute change from baseline in
Headache Impact Test (HIT-6) Score: AB6 vs Placebo




FIG. 7
HIT-6 Responder Analysis
Percent patients who are some or little/none life
impact for headache impact score (HIT-6) versus time:
AB6 vs Placebo




FIG. 8.
PK Profile
Ab6 1000 mg I.V.
Mean +/- SD




FIG. 9.
PK Parameters

Plasma Free Ab6*

	C _{max} (µg/mL)	AUC _{0-∞} (mg*hr/mL)	Half-Life (Days)	Vz (L)	CL (mL/hr)
N	81	78	78	78	78
Mean	336	219	31	5.2	5.0
SD	80	64	8	2.1	1.5

* - Following 1000 mg Ab6 IV single-dose

FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22

Mean (±SD) Change from Baseline In Study Endpoints						
Endpoint	Weeks 1-4		Weeks 5-8		Weeks 9-12	
	Placebo i.v. (n=82)	Ab6 1000mg i.v. (n=81)	Placebo i.v. (n=82)	Ab6 1000mg i.v. (n=81)	Placebo i.v. (n=82)	Ab6 1000mg i.v. (n=81)
Migraine Days	-3.9 (3.5)	-5.6 (3.3) ¹	-4.6 (3.6)	-5.6 (3.0) ²	-4.6 (3.5)	-5.6 (4.0) ³
Migraine Episodes	-3.0 (2.7)	-3.7 (2.4)	-3.7 (2.9)	-3.8 (2.2)	-3.7 (2.8)	-3.9 (2.6)
Migraine Hours	-33.7 (41.8)	-58.0 (49.1)	-36.1 (45.9)	-54.4 (48.3)	-37.1 (40.0)	-54.6 (60.5)
Average Migraine Severity ⁴	-0.16 (0.58)	-0.31 (0.58)	-0.10 (0.54)	-0.16 (0.50)	-0.08 (0.54)	-0.11 (0.43)
Headache Frequency	-4.0 (3.8)	-5.6 (3.4)	-5.0 (3.7)	-5.3 (3.5)	-5.1 (3.7)	-5.9 (3.8)
HIT-6 score	-5.8 (7.8)	-10.2 (9.8)	-8.1 (8.9)	-9.9 (9.7)	-7.7 (9.0)	-10.1 (10.6)
MSQ RFP	19.9 (23.8)	29.3 (24.3)	25.2 (24.8)	28.8 (24.7)	22.2 (23.1)	28.5 (24.5)
MSQ RFR	16.3 (23.2)	21.1 (23.9)	20.2 (22.1)	20.9 (23.3)	18.0 (20.5)	21.4 (23.1)
MSQ EF	19.4 (27.6)	25.1 (28.3)	21.2 (25.1)	23.8 (25.8)	21.1 (25.1)	23.1 (26.8)

¹p<0.001; ²p=0.03; ³p=0.06; ⁴ Severity measured on a 4 point scale with 1 = mild and 4 = severe

FIG. 23




FIG. 24.
Chronic migraine $\geq 50\%$ responder rates




FIG. 25.
Chronic migraine $\geq 75\%$ responder rates




FIG. 26.
Chronic migraine 100% responder rates




FIG. 27

	Placebo	100 mg	300 mg
Subjects, n	366	356	350
Mean age, years (SD)	39.6 (11.3)	41.0 (11.7)	41.0 (10.4)
Mean BMI, kg/m ² (SD)	27.0 (5.6)	26.4 (5.0)	26.3 (5.0)
Female, %	89	86	90
Mean years from migraine diagnosis	17.0	18.3	19.0
Mean duration of chronic migraine, years (SD)	11.6 (10.9)	11.6 (11.7)	12.4 (11.2)
≥1 prophylactic medication, n (%) [*]	163 (44.5)	161 (45.2)	155 (44.3)
Mean migraine days/month (SD)	16.2 (4.6)	16.1 (4.6)	16.1 (4.8)
Mean headache days/month (SD)	20.6 (3.0)	20.4 (3.1)	20.4 (3.2)

FIG. 28.
Difference from placebo in change from baseline in mean
migraine days (MMD) over months 1-3 by baseline subgroup




FIG. 29.
Difference from placebo in change from baseline in mean
migraine days (MMD) over months 1-3 by baseline subgroup




FIG. 30.




FIG. 31.




FIG. 32.




FIG. 33.

	Month 1			Month 6		
	Ab6 100 mg	Ab6 400 mg	Placebo	Ab6 100 mg	Ab6 400 mg	Placebo
Baseline use						
1–9 days/month, n	37	49	49	37	49	49
≥10 days/month, n	264	265	260	264	265	260
≥1 day/month, mean (SD)	18.3 (9.05)	18.4 (9.61)	17.9 (8.60)	18.3 (9.05)	18.4 (9.61)	17.9 (8.60)
Post-baseline use, mean (SD)						
≥1 day/month	10.7 (9.39)	10.2 (9.87)	13.8 (9.52)	10.8 (11.18)	8.6 (9.97)	11.5 (10.16)
Change from baseline, mean (SD)						
≥1 day/month	-7.8 (8.08)	-8.3 (7.64)	-4.5 (7.46)	-8.1 (9.90)	-9.6 (9.92)	-7.0 (9.39)
1–9 days/month	-1.5 (4.44)	-2.3 (4.34)	-1.0 (5.29)	-0.8 (6.63)	-2.6 (4.57)	-1.3 (4.83)
≥10 days/month	-8.7 (8.08)	-9.4 (7.62)	-5.1 (7.63)	-8.9 (9.88)	-11.1 (10.10)	-7.9 (9.64)
Percent change from baseline, mean (SD)						
≥1 day/month	-42.6 (39.98)	-47.0 (40.90)	-22.4 (52.02)	-40.7 (60.66)	-52.9 (48.97)	-34.7 (58.48)
1–9 days/month	-31.8 (67.95)	-47.3 (65.38)	-9.5 (100.52)	1.4 (132.84)	-45.0 (73.05)	-11.2 (108.44)
≥10 days/month	-44.1 (34.24)	-47.0 (34.73)	-24.8 (36.17)	-45.3 (44.91)	-54.5 (42.52)	-38.5 (44.63)

FIG. 34.




FIG. 35.





FIG. 36.



Summary of Acute Medication Days by Subgroups of Episodic Migraine Patients with Baseline Acute Medication Use

FIG. 37.

	Month 1			Month 6		
	Ab6 100 mg	Ab6 400 mg	Placebo	Ab6 100 mg	Ab6 400 mg	Placebo
Baseline use						
1–9 days/month, n	117	111	108	117	111	108
≥10 days/month, n	42	41	44	42	41	44
≥1 day/month, mean (SD)	7.5 (4.97)	7.5 (4.58)	7.8 (4.98)	7.5 (4.97)	7.5 (4.58)	7.8 (4.98)
Post-baseline use, mean (SD)						
≥1 day/month	4.3 (3.99)	4.2 (4.45)	5.7 (5.04)	4.2 (5.87)	3.5 (3.92)	5.1 (5.19)
Change from baseline, mean (SD)						
≥1 day/month	-3.3 (4.14)	-3.2 (4.20)	-2.2 (4.68)	-2.8 (4.92)	-4.1 (4.60)	-2.3 (4.69)
1–9 days/month	-2.0 (2.91)	-2.2 (3.57)	-1.3 (3.10)	-2.4 (3.11)	-2.7 (3.83)	-1.6 (3.52)
≥10 days/month	-6.6 (5.11)	-5.8 (4.66)	-4.3 (6.82)	-4.0 (8.60)	-7.4 (4.60)	-4.1 (6.60)
Percent change from baseline, mean (SD)						
≥1 day/month	-36.9 (63.96)	-39.4 (77.71)	-22.4 (60.27)	-45.4 (62.28)	-50.9 (59.88)	-22.5 (95.61)
1–9 days/month	-33.9 (72.22)	-37.0 (88.45)	-19.7 (64.62)	-50.1 (59.65)	-48.2 (68.26)	-18.2 (107.55)
≥10 days/month	-45.1 (30.26)	-45.9 (34.95)	-29.1 (47.94)	-29.2 (69.14)	-57.2 (32.59)	-33.9 (52.53)

FIG. 38




FIG. 39.
Simulation of 50 mg Lu AG09222 given subcutaneously
monthly for 7 months

